Grifols (GRFS) Total Non-Current Liabilities (2009 - 2025)
Grifols' (GRFS) quarterly Total Non-Current Liabilities came in at $11.7 billion in Q4 2025, up 3.27% YoY from $11.4 billion in Q4 2024, and up 3.27% on a QoQ basis from $11.4 billion in Q4 2024.
Grifols (GRFS) Total Non-Current Liabilities (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Total Non-Current Liabilities data on file, last reported at $11.7 billion in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 3.27% year-over-year to $11.7 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.7 billion (up 3.27% YoY) and the FY2025 annual result came in at $11.7 billion, up 20873.57% from the prior year.
- Total Non-Current Liabilities improved to $11.7 billion in Q4 2025, from $11.4 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $12.0 billion in Q4 2023 to a low of $9.7 billion in Q4 2021.
- A 5-year average of $11.2 billion and a median of $11.5 billion in 2022 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities advanced 18.68% — and 2024, when it declined 5.22%.
- Tracing GRFS's Total Non-Current Liabilities over 5 years: stood at $9.7 billion in 2021, then gained by 18.68% to $11.5 billion in 2022, then advanced by 4.7% to $12.0 billion in 2023, then slipped by 5.22% to $11.4 billion in 2024, then advanced by 3.27% to $11.7 billion in 2025.
- The last three Total Non-Current Liabilities figures came in at $11.7 billion (Q4 2025), $11.4 billion (Q4 2024), and $12.0 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.95 Bn | 632.19 Bn | 17.26 Bn | 105.99 Bn |
| 2 | AbbVie | 469.97 Bn | 463.40 Bn | 12.70 Bn | 100.51 Bn |
| 3 | Merck | 377.05 Bn | 369.90 Bn | 12.21 Bn | 122.23 Bn |
| 4 | Novartis Ag | 302.66 Bn | 294.97 Bn | 11.24 Bn | 48.34 Bn |
| 5 | Astrazeneca | 258.09 Bn | 253.19 Bn | 12.86 Bn | 33.91 Bn |
| 6 | Amgen | 236.99 Bn | 223.00 Bn | 7.24 Bn | 92.80 Bn |
| 7 | Gilead Sciences | 183.08 Bn | 179.90 Bn | 6.22 Bn | 47.87 Bn |
| 8 | Pfizer | 160.54 Bn | 148.84 Bn | 10.94 Bn | 100.86 Bn |
| 9 | Gsk | 106.06 Bn | 101.89 Bn | 8.24 Bn | -30.89 Bn |
| 10 | Grifols | 5.47 Bn | 4.47 Bn | - | 11.75 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.75 Bn |
| Dec 31, 2024 | 11.37 Bn |
| Dec 31, 2023 | 12.00 Bn |
| Dec 31, 2022 | 11.46 Bn |
| Dec 31, 2021 | 9.66 Bn |
| Dec 31, 2020 | 8.61 Bn |
| Sep 30, 2020 | 8.52 Bn |
| Mar 31, 2020 | 8.12 Bn |
| Dec 31, 2019 | 8.11 Bn |
| Sep 30, 2019 | 8.18 Bn |
| Dec 31, 2018 | 7.45 Bn |
| Sep 30, 2018 | 7.61 Bn |
| Jun 30, 2018 | 7.69 Bn |
| Mar 31, 2018 | 8.96 Bn |
| Dec 31, 2017 | 7.43 Bn |
| Jun 30, 2017 | 7.29 Bn |
| Dec 31, 2016 | 5.75 Bn |
| Sep 30, 2016 | 5.70 Bn |
| Jun 30, 2016 | 5.82 Bn |
| Dec 31, 2015 | 5.75 Bn |